JAK1 and glioma: Specifically, the combined treatment reduced H3K27ac levels on several enhancers linked to genes involved in mTOR pathway and gliomagenesis, such as AKT3, JAK1, and NFKB2 genes, that were shown to have critical role in malignant gliomas (Peng et al., 2022; Mure et al., 2010; Ding et al., 2020; Tu et al., 2011; Raychaudhuri et al., 2007), SEC13 gene that indirectly activates mTOR (Bar-Peled et al., 2013; Cai et al., 2016), and CD93, a key regulator in glioma (Langenkamp et al., 2015; Figure 3G and Figure 3—figure supplement 1H).